JYNT:NASDAQThe Joint Corp. Analysis
Data as of 2026-08-26 - not real-time
$8.45
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
The moving-average structure behind The Joint Corp. is bearish at $8.45, with short-term averages lagging the long-term ones. Over a rolling month the price has lost 5.6%. Relative strength is 48.5 — neutral — and the MACD signal is bullish. The recent range runs from support at $7.96 up to resistance at $8.91.
Multiples put this in overvalued territory: 60.4 times earnings against the sector's 31.2. Sell-side targets cluster 18.3% above the current quote. Revenue is growing at 14.4% on a 6.5% profit margin.
The composite risk read is 7/10, putting it in elevated territory. With 30-day volatility of 28.4%, a beta of 0.82 and a maximum drawdown of 29.5%, position sizing matters more than entry timing here. Thin trading volumes mean execution costs can be material on larger orders. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
Near-term and long-term part ways here — sell short-term against hold longer out, with 2/10 conviction on the long call.
Multiples put this in overvalued territory: 60.4 times earnings against the sector's 31.2. Sell-side targets cluster 18.3% above the current quote. Revenue is growing at 14.4% on a 6.5% profit margin.
The composite risk read is 7/10, putting it in elevated territory. With 30-day volatility of 28.4%, a beta of 0.82 and a maximum drawdown of 29.5%, position sizing matters more than entry timing here. Thin trading volumes mean execution costs can be material on larger orders. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
Near-term and long-term part ways here — sell short-term against hold longer out, with 2/10 conviction on the long call.
Top Market Events
The Joint Corp JYNT reports a 14% revenue surge and a $1.- Consolidated Net Income Increases $560,000 to $653,000; Adjusted EBITDA From Continuing Operations Increases by $1.Seeking Alpha18dThe Joint Corp. JYNT Q2 2026 Earnings Call TranscriptThank you for standing by. My name is Rebecca, and...
Market Outlook
Short Term
< 1 yearCautious
Model confidence: 4/10
Key Factors
- Short-term moving averages stacked below long-term ones
- Trading below the 200-day average of 8.81
- MACD momentum is positive
Medium Term
1–3 yearsCautious
Model confidence: 4/10
Key Factors
- Short-term moving averages stacked below long-term ones
- P/E of 60.4 versus sector average of 31.2
- Trading below the 200-day average of 8.81
Long Term
> 3 yearsNeutral
Model confidence: 2/10
Key Factors
- P/E of 60.4 versus sector average of 31.2
- Analyst targets imply +18.3% versus the current price
- Revenue growth of +14.4%
Key Metrics & Analysis
Financial Health
Revenue Growth14.40%
Profit Margin6.49%
P/E Ratio60.4
ROE10.62%
ROA2.33%
Debt/Equity12.83
P/B Ratio7.3
Op. Cash Flow$5.4M
Free Cash Flow$4.0M
Industry P/E31.2
Technical Analysis
TrendBearish
RSI48.5
Support$7.96
Resistance$8.91
MA 20$8.39
MA 50$8.71
MA 200$8.81
MACDBullish
VolumeDecreasing
Fear & Greed Index93.84
Valuation
Fair Value$7.96
Target Price$10.00
Upside/Downside18.34%
GradeOvervalued
TypeGrowth
Risk Assessment
Beta0.82
Volatility28.44%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskHigh
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.